Funding has been flowing into biotech over the past few years.
Over one week earlier this year, biotech and healthcare startups raised almost $1 billion in capital. And on Tuesday, a cancer-drug startup called Allogene raised $300 million in its series A round.
{iframe}http://www.businessinsider.com/aisling-capitals-steve-elms-on-the-rise-of-massive-early-funding-rounds-2018-4?r=UK&IR=T{/iframe}